A Phase 2 interventional study of TQC3721 suspension for inhalation and TQC3721 matching placebo for inhalation in Chronic Obstructive Pulmonary Disease, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 11 sites in China. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-17.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.
Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 11th largest by enrollment, is the only one that started in 2023, is one of 8 in phase 2, and was the 4th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 40–80
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 40–80
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2023.
This study's enrollment of 75 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 113 across the 17 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Chia Tai Tianqing Pharmaceutical Group Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
4 of the studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07464587Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-02 |
| NCT07147946Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-03 |
| NCT06707883Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | 2026-12 |
| NCT06789289Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | 2027-03-17 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase II clinical trial to evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
COVID-19:
History or current evidence of cardiovascular diseases with clinical significance. It is defined as any disease that the investigator believes will endanger the safety of patients when participating in the study, or any disease that may affect the effectiveness or safety analysis if the disease/condition worsens during the study; Subjects who have experienced any of the following conditions during visit 1 will be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TQC3721 suspension for inhalation, twice a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.
Drug: TQC3721 suspension for inhalation · Drug: Salbutamol sulfate inhalation aerosol
TQC3721 suspension for inhalation, once a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.
Drug: TQC3721 suspension for inhalation · Drug: Salbutamol sulfate inhalation aerosol
TQC3721 suspension placebo for inhalation, twice a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.
Drug: TQC3721 matching placebo for inhalation · Drug: Salbutamol sulfate inhalation aerosol
TQC3721 suspension placebo for inhalation, once a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.
Drug: TQC3721 matching placebo for inhalation · Drug: Salbutamol sulfate inhalation aerosol
TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.
Placebo without active substance.
Salbutamol is short-acting β2 receptor agonists.
The peak of Forced Expiratory Volume in the 1st second (FEV1) (4 weeks)
Change of the maximum value of FEV1 from baseline to four weeks after treatment
Time frame: From baseline to four weeks after treatment.
Morning trough FEV1
The FEV1 before administration
Time frame: From baseline to four weeks after treatment.
Average FEV1 (4 weeks)
Average FEV1 of 3 hours, 12 hours, 24 hours, 0-12 hours and 12-24 hours after administration.
Time frame: From baseline to four weeks after treatment.
Changes in FEV1
Changes in FEV1 at each time point within 24 hours after administration
Time frame: From baseline to four weeks after treatment.
COPD Assessment Test (CAT)
Change From Baseline to four weeks after treatment. The score range is 0 to 40 points (0 to 10 is minor influence; 11 to 20 are moderate; 21 to 30 are classified as severe impact; 31 to 40 is very severe).
Time frame: From baseline to four weeks after treatment.
Modified Medical Research Council (mMRC) Dyspnea Scale Score
Change From Baseline to four weeks after treatment in mMRC Scoring. The questionnaire is mainly used to evaluate the degree of respiratory distress in patients with chronic obstructive pulmonary disease. According to the symptoms of respiratory distress, the questionnaire is divided into 5 levels, with 0-1 points as less symptoms and ≥ 2 points as more symptoms.
Time frame: From baseline to four weeks after treatment.
The peak of FEV1 (two weeks)
Change of the maximum value of FEV1 from baseline to two weeks after treatment
Time frame: From baseline to two weeks after treatment.
Trough FEV1
Change of trough FEV1 from baseline to two weeks after treatment.
Time frame: From baseline to two weeks after treatment.
Average FEV1 within 3 hours
Average FEV1 within 3 hours after administration
Time frame: From baseline to two weeks after treatment
Frequency of Rescue medication
Frequency of Rescue medication used group during the study in the experimental compared to that in the placebo group.
Time frame: From baseline to four weeks after administration.
Plasma drug peak concentration (Cmax)
Plasma drug peak concentration after administration.
Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Time to maximum concentration (Tmax)
Time to maximum concentration (Tmax) after administration.
Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Area Under Curve (AUC)
Area under the drug concentration-time curve.
Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Elimination half-life (t1/2)
Apparent terminal elimination half-life after drug administration.
Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Apparent volume of distribution (Vd)
Apparent volume of distribution after drug administration.
Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Clearance (CL)
The total drug clearance rate of liver, kidney, etc.
Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Plasma concentration at steady state (Cav, SS)
The plasma concentration at which the rate of administration and rate of elimination are in equilibrium.
Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Minimum concentration (Cmin)
Plasma drug minimum concentration after administration.
Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Degree of fluctuation (DF)
The ratio of the difference between Cmax,ss and Cmin,ss to Cav,ss.
Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Steady state volume of distribution (Vss)
Steady state volume of distribution after administration.
Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Number of cases of adverse events
Number of cases of adverse events assessed by Common Terminology Criteria for Adverse Events ( CTCAE ) v5.0.
Time frame: From baseline to four weeks after treatment.
Incidence of adverse events
Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events ( CTCAE ) v5.0.
Time frame: From baseline to four weeks after treatment.
Number of cases of serious adverse events.
Number of cases of serious adverse events assessed by Common Terminology Criteria for Adverse Events ( CTCAE ) v5.0.
Time frame: From baseline to four weeks after treatment.
Incidence of serious adverse events.
Incidence of serious adverse events assessed by Common Terminology Criteria for Adverse Events ( CTCAE ) v5.0.
Time frame: From baseline to four weeks after treatment.
Number of cases of adverse events related to study drug.
Number of cases of adverse events related to study drug assessed by CTCAE v5.0.
Time frame: From baseline to four weeks after treatment.
Incidence of adverse events related to study drug.
Incidence of adverse events related to study drug assessed by CTCAE v5.0.
Time frame: From baseline to four weeks after treatment.
The peak of FEV1 (Day 1).
Change of the maximum value of FEV1 from baseline to Day 1.
Time frame: From baseline to Day 1.
The peak of FEV1 (Day 1 to 4 weeks)
Change of the maximum value of FEV1 from Day 1 to four weeks after treatment
Time frame: From Day 1 to four weeks after treatment.
Average FEV1 (Day 2)
Average FEV1 of 3 hours, 12 hours, 24 hours, 0-12 hours and 12-24 hours after administration.
Time frame: From baseline to 24 hours after first treatment.
Average FEV1 (Day 1 to 4 weeks)
Average FEV1 of 3 hours, 12 hours, 24 hours, 0-12 hours and 12-24 hours after administration.
Time frame: From Day 1 to four weeks after treatment.
Ran from Aug 2023 to primary completion in Jan 2024, 4 months.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 4 months is below that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TQC3721
Pulmonary Disease, Chronic Obstructive →
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →